Market revenue in 2023 | USD 172.7 million |
Market revenue in 2030 | USD 342.6 million |
Growth rate | 10.3% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Infectious Diseases |
Historical data | 2021 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Infectious Diseases |
Key market players worldwide | Danaher Corp, Kaneka Corp, TriLink BioTechnologies, Apex Biotechnology, BioNTech SE ADR, Lonza Group Ltd, Nunn’s Home Medical Equipment, EQT Corp, Catalent Inc, Samsung Electronics Co Ltd, Biomay AG, Indication, eTheRNA immunotherapies, BioCina |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics contract development & manufacturing market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the France mrna therapeutics contract development & manufacturing market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
Growing funding by leading companies to develop mRNA vaccines in France is expected to accelerate market growth during the forecast period. For instance, in March 2022, Sanofi announced plans to invest EUR 935 million (USD 1.1 billion) between 2022 and 2026 to produce mRNA-based vaccines with a complete and independent mRNA value chain in France.
Growing investments in mRNA-based treatments are expected to present lucrative opportunities in the market. Moreover, rising approvals of mRNA-based vaccines in the region are projected to fuel market growth over the forecast period.
For instance, in September 2022, three bivalent mRNA vaccines against the COVID-19 Omicron variant were approved by The French National Health Authority (HAS). Thus, increasing approvals of mRNA-based vaccines by government bodies are likely to increase the demand for mRNA therapies in the near future.
Horizon Databook provides a detailed overview of country-level data and insights on the France mrna therapeutics contract development & manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into France mrna therapeutics contract development & manufacturing market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account